Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24408874 | 0.88 | GPR119 (0.46) | GPR119HRH3KMT2ANAMPT | |
| SCHEMBL28753038 | 0.85 | GPR119 (0.47) | GPR119HRH3 | |
| SCHEMBL22520476 | 0.83 | GPR119 (0.52) | GPR119HRH3NAMPT | |
| SCHEMBL29634691 | 0.81 | GPR119 (0.54) | GPR119HRH3NAMPT | |
| SCHEMBL25343723 | 0.81 | GPR119 (0.49) | GPR119HRH3KMT2ASMN1; SMN2 | |
| SCHEMBL15367071 | 0.80 | GPR119 (0.42) | GPR119HRH3NAMPTACACB | |
| SCHEMBL23317472 | 0.79 | ACACB (0.35) | GPR119HRH3ACACB | |
| SCHEMBL31059139 | 0.79 | ACACB (0.35) | GPR119HRH3ACACB | |
| SCHEMBL20270723 | 0.79 | GPR119 (0.53) | GPR119HRH3KMT2AMEN1 | |
| SCHEMBL13919430 | 0.79 | GPR119 (0.53) | GPR119HRH3KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022095971-A1 | SPIRO HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海医药集团股份有限公司 | 2022-05-12 | — | — | WO | disclosed |